High concentration anti-TNFα antibody liquid formulations

US8821865B2 · kind B2 · utility

Assignee

• AbbVie Biotechnology Ltd. · BM

Inventors

• Michael Neu · Edingen-Neckarhausen, DE
• Markus Tschoepe · Heßheim, DE
• Carsten Weber · Frankenthal (Pfalz), DE
• Wolfgang Fraunhofer · Gurnee, US
• Laura Redden · Glenview, US
• Martin Gastens · Monsheim, DE
• Alexander Feick · Allschwil, CH

Key dates

• Filing date: Nov 11, 2011
• Grant date: Sep 2, 2014
• Expiry date: Nov 11, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.